Literature DB >> 6459367

Human T cell subpopulations defined by a monoclonal antibody. II. Evidence for cell cooperation in the response to alloantigens and generation of cytolytic cells.

A Moretta, G Corte, M C Mingari, L Moretta.   

Abstract

It has been shown previously that the 5/9 monoclonal antibody defines a small T cell subpopulation in human peripheral blood that includes all the cells responsible for proliferation to tetanus toxoid and to alloantigens as well as the helper cells for B cell differentiation. In the present study, human peripheral blood T cells were fractionated according to their reactivity with the 5/9 monoclonal antibody and stimulated in mixed lymphocyte culture (MLC). In spite of a strong proliferative response in MLC, 5/9+ cells generated no cytolytic activity against PHA-activated lymphocytes bearing the stimulating alloantigens (CTL activity) or against the K562 human cell line (NK activity). The precursors of these cytolytic effector cells were present in the 5/9- fraction. However, 5/9+ cells or soluble factors derived from 5/9+ cells were needed to induce 5/9- cells to respond in MLC and develop cytolytic activity. Both 5/9+ and 5/9- cell populations, upon MLC stimulation, were able to lyse L1210 mouse lymphoma cells in the presence of specific antibodies (ADCC).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6459367

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Clonal analysis of liver-derived T cells of patients with primary biliary cirrhosis.

Authors:  R M Hoffmann; G R Pape; U Spengler; E P Rieber; J Eisenburg; J Döhrmann; G Paumgartner; G Riethmüller
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

2.  Direct demonstration of the clonogenic potential of every human peripheral blood T cell. Clonal analysis of HLA-DR expression and cytolytic activity.

Authors:  A Moretta; G Pantaleo; L Moretta; J C Cerottini; M C Mingari
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

3.  Incidence of T cell subset imbalance in relatives of Graves' disease patients.

Authors:  P Biassoni; G Ciprandi; S Ferrini; G Chimini; G W Canonica; M Bagnasco
Journal:  J Endocrinol Invest       Date:  1984-04       Impact factor: 4.256

4.  Pulmonary sarcoidosis: excess of helper T lymphocytes and T cell subset imbalance at sites of disease activity.

Authors:  G A Rossi; O Sacco; E Cosulich; G Damiani; G Corte; A Bargellesi; C Ravazzoni
Journal:  Thorax       Date:  1984-02       Impact factor: 9.139

5.  Functional characterization of a regulatory human T-cell subpopulation increasing during autologous MLR.

Authors:  M E Cosulich; A Risso; G W Canonica; A Bargellesi
Journal:  Immunology       Date:  1986-02       Impact factor: 7.397

6.  Circulating T cell subsets in euthyroid Graves' disease.

Authors:  M Bagnasco; G W Canonica; S Ferrini; G Ciprandi; W Dirienzo; G Giordano; O Ferrini
Journal:  J Endocrinol Invest       Date:  1983-04       Impact factor: 4.256

7.  Autoimmune thyroid disease: purification and phenotypic analysis of intrathyroid T cells.

Authors:  G W Canonica; M Caria; G Torre; A Risso; M E Cosulich; M Bagnasco
Journal:  J Endocrinol Invest       Date:  1984-12       Impact factor: 4.256

8.  A monoclonal anti-DC1 antibody selectivity inhibits the generation of effector T cells mediating specific cytolytic activity.

Authors:  G Corte; A Moretta; M E Cosulich; D Ramarli; A Bargellesi
Journal:  J Exp Med       Date:  1982-11-01       Impact factor: 14.307

9.  Clonal heterogeneity in the requirement for T3, T4, and T8 molecules in human cytolytic T lymphocyte function.

Authors:  A Moretta; G Pantaleo; M C Mingari; L Moretta; J C Cerottini
Journal:  J Exp Med       Date:  1984-03-01       Impact factor: 14.307

10.  Quantitative assessment of the pool size and subset distribution of cytolytic T lymphocytes within human resting or alloactivated peripheral blood T cell populations.

Authors:  A Moretta; G Pantaleo; L Moretta; M C Mingari; J C Cerottini
Journal:  J Exp Med       Date:  1983-08-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.